Company Profile

ONCODESIGN specializes in preclinical pharmacological evaluation services of new cancer therapies on behalf of the pharmaceutical and biotechnological companies. The group also provides research and development of drugs and biomarkers primarily for the treatment of cancer. The group's activity is organized around 3 business units: - Service: discovery, identification and selection of new therapeutic targets in oncology; - Biotech: development of a portfolio of therapeutic and diagnostic projects alone or through partnerships; - Artificial Intelligence: development of a platform for selecting new therapeutic targets in oncology. 60.3% of sales are abroad.

Employees

236

Sector

Biotechnology & Medical Research

More about the company

21/12/22	Oncodesign Société Anonyme(ENXTPA:ALONC) dropped from Next Biotech Index	CI
19/10/22	Oncodesign Services Names Successors as Chairman/CEO Departs	MT
19/10/22	Oncodesign Services Shareholders Sell Majority Stake to Edmond de Rothschild Fund	MT
05/10/22	Oncodesign Precision Medicine to List Directly on Euronext Access + Paris	MT
05/10/22	Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	CI
05/10/22	Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	CI
29/09/22	Oncodesign Unit Gains Approval To List On Euronext Access + In Paris	MT
28/09/22	Oncodesign Société Anonyme agreed to Spin-Off Oncodesign Precision Medicine.	CI
01/07/22	Oncodesign Société Anonyme Announces Planned Separation of Its Two Business Areas	CI
07/04/22	Oncodesign Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021	CI
08/02/22	Sengine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors	CI
27/01/22	Oncodesign Société Anonyme Reports Turnover Results for the Year Ended December 31, 2021	CI
24/12/21	Oncodesign Société Anonyme's Equity Buyback announced on February 15, 2021, has expired.	CI

26/10/22	ONCODESIGN : Franchissement de seuil	PU
19/10/22	ONCODESIGN : Inside Information / Operations of the issuer (acquisitions, sales...)	PU
03/10/22	The General Meeting of Oncodesign authorises the allocation of Oncodesign Precision Medicine shares to Oncodesign shareholders	AQ
29/09/22	Euronext Paris authorises the listing of Oncodesign Precision Medicine shares on Euronext Access + in connection with the allocation of OPM shares to Oncodesign shareholders	AQ
27/09/22	Parkinson, Servier exercises the exclusive licensing option on collaborative program with Oncodesign Precision Medicine	AQ

13/12/22	ONCODESIGN : Communiqués publiés en période d'offre publique d'acquisition / OPA Autres communiqués
06/12/22	Bolsa de Madrid: Es la economía, estúpido
06/12/22	Les valeurs à suivre aujourd'hui à la Bourse de Paris - Mardi 6 décembre 2022
06/12/22	En Direct des Marchés : Saint-Gobain, EssilorLuxottica, Veolia, Voltalia, Catana, Porsche, SKF, PepsiCo...
06/12/22	C'est l'économie, crétin

Manager	Title	Age	Since
Fabrice Viviani CEO	Chief Executive Officer	-	05/11/2022
Arnaud Lafforgue DFI	Director of Finance/CFO	-	24/04/2018
Stéphane Gerart CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Karine Lignel BRD	Director/Board Member	58	14/05/2008
Kamel Besseghir BRD	Director/Board Member	78	03/02/2014
Aline Aubertin BRD	Director/Board Member	-	24/06/2021

ONCODESIGN Stock

Stocks

ALONC

FR0011766229

Biotechnology & Medical Research

Latest news : ONCODESIGN

Press Releases: ONCODESIGN

News in other languages: ONCODESIGN

Managers and Directors: ONCODESIGN

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
17/12/22	Fabrice Viviani	Buy	Chief Executive Officer	18,480	0.2673%
24/10/22	Thierry Billoué	Sell	Head of Human Resources	18,140	0.2649%
24/10/22	Sylvie Fernandes Forster	Sell	General Counsel	15,120	0.2208%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCODESIGN	-.--%	-0.14%	-	-	105M
LONZA GROUP AG	-0.35%	+0.97%	-15.96%	-12.73%	42.96B
REVOLUTION MEDICINES, INC.	+3.09%	+3.00%	+273.87%	+507.27%	31.73B
IQVIA HOLDINGS INC.	-0.47%	-2.15%	+12.81%	-15.29%	30.22B
BEONE MEDICINES AG	+1.72%	-1.77%	-4.05%	+24.45%	28.94B
CELLTRION, INC.	+4.09%	-1.98%	+11.99%	+17.37%	23.87B
MEDPACE HOLDINGS, INC.	-0.60%	+3.48%	+54.62%	+115.59%	13.57B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.06%	+7.59%	12.96B
ASCENDIS PHARMA A/S	+2.49%	+5.29%	-	-	13.39B
IONIS PHARMACEUTICALS, INC.	-1.19%	-2.15%	+104.59%	+75.05%	12.2B
Average	+0.81%	-0.71%	+55.49%	+89.92%	23.31B
Weighted average by Cap.	+1.00%	-1.08%	+54.24%	+95.65%